| design therapeutic strategies | pathogenesis for | 2019-nCoV (count: 3) | |
|---|---|
| Our findings may explain the clinical symptoms so far and help clinicians and researchers understand the pathogenesis and design therapeutic strategies for 2019-nCoV. : medRxiv preprint GO biological process annotation gmt file was downloaded from MSigDB (https://www.gsea-msigdb.org/gsea/msigdb/).
-- Integrative Bioinformatics Analysis Provides Insight into the Molecular Mechanisms of 2019-nCoV. medrxiv. 2020-02-05. | |
| Considering the sequence of 2019-nCoV is similar to the SRAS-CoV and they are reported to share the same molecular as the entry point, analyses of ACE2 expression and distribution in lung and related biological processes may help us understand the pathogenesis and design therapeutic strategies for 2019-nCoV. Recent advances in bioinformatics enable researchers to reveal the underlying mechanisms of various diseases.
-- Integrative Bioinformatics Analysis Provides Insight into the Molecular Mechanisms of 2019-nCoV. medrxiv. 2020-02-05. | |
| These results may help us understand the pathogenesis and design therapeutic strategies for 2019-nCoV.
-- Integrative Bioinformatics Analysis Provides Insight into the Molecular Mechanisms of 2019-nCoV. medrxiv. 2020-02-05. | |
| clinical trials | have | have registered since beginning of COVID-19 outbreak (count: 2) | |
| Numerous clinical trials have been registered since the beginning of the COVID-19 outbreak, however, a number of information regarding drugs or trial design were lacking.
-- reference not found! | |
| 8 Concomitantly, numerous clinical trials have been registered since the beginning of the COVID-19 outbreak numerous to evaluate therapeutic strategies for this disease.
-- reference not found! | |
| PARP1 inhibitor CVL218 | can serve as | potential therapeutic agent for treatment of COVID-19 (count: 1) | |
| In summary, the PARP1 inhibitor CVL218 discovered by our data-driven drug repositioning framework can serve as a potential therapeutic agent for the treatment of COVID-19.
| |
| vital role | is in | current therapeutics against SARS-CoV-2 (count: 1) | |
| e964.pdf), which also highlights the vital role of anti-inflammatory response in current therapeutics against SARS-CoV-2.
| |
| lung | is therapeutically targeted tissue for | COVID-19 (count: 1) | |
| Such a tissue specific enrichment in lung may bring an extra advantage for CVL218 to be used for the anti-SARS-CoV-2 purpose, as lung is the therapeutically targeted tissue for COVID-19.
| |
| dosage | ensure | therapeutic efficacy against SARS-CoV-2 (count: 1) | |
| Moreover, high level distribution in lung may also suggest that only low dosage is needed in order to ensure the therapeutic efficacy of CVL218 against SARS-CoV-2, which may further reduce the risk of adverse events.
| |
| we | screen | potential therapeutic drug candidates against COVID-19 (count: 1) | |
| Due to the lack of gene expression data from the SARS-CoV-2 infected patients, we used those from the SARS-CoV infected patients to screen the potential therapeutic drug candidates against COVID-19.
| |
| therapeutic challenge | is attributed to | rigidity of COVID-19 RBD (count: 1) | |
| This implies a therapeutic challenge is attributed to the enhanced rigidity of the COVID-19 RBD relative to that of the SARS-2002.
-- The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor. biorxiv. 2020-03-12. | |
| drugs | provide | therapeutic options for patients with COVID-19 (count: 1) | |
| In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.
-- reference not found! | |
| pilot study | showed | potential therapeutic effect in treatment of COVID-19 patients (count: 1) | |
| In conclusion, this pilot study on CP therapy showed a potential therapeutic effect and low risk in the treatment of severe COVID-19 patients.
-- reference not found! | |
| COVID-19-related interventional clinical trials | have emerged | area (count: 1) | |
| Recently, many COVID-19-related interventional clinical trials have emerged in China, the original and high-incidence area of COVID-19 1 .
-- Appealing for Efficient, Well Organized Clinical Trials on COVID-19. medrxiv. 2020-03-07. | |
| therapeutic design | should start with | SARS-CoV-2 S protein de novo (count: 1) | |
| Therefore, antibody-based therapeutic design should start with the SARS-CoV-2 S protein de novo.
-- reference not found! | |
| having | therapeutic potential with | scope for SARS-CoV-2 (count: 1) | |
| In addition, our immune-informatics based pipeline also provides a framework to identify B-and T-cell epitopes having therapeutic potential with excellent scope for SARS-CoV-2, but not limited to specific virus.
-- Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. biorxiv. 2020-02-27. | |
| We | generate | therapeutic candidates for 2019-nCoV (count: 1) | |
| The present work makes use of a recently developed generative network complex (GNC) 17 to explore potential protease inhibitors for curing 2019-nCoV. We generate anticoronaviral therapeutic candidates for 2019-nCoV and evaluate their druggable properties.
-- Machine intelligence design of 2019-nCoV drugs. biorxiv. 2020-02-04. | |
| heparin | prerequisite for | research related to development of SARS-CoV-2 therapeutic (count: 1) | |
| Here, we describe preliminary tests for the ability of the SARS-CoV-2 S1 RBD to bind heparin, an important prerequisite for the underpinning research related to the development of SARS-CoV-2 heparin-based therapeutic.
| |
| manufacturing | strategy | responding to COVID-19 for development of generation therapeutics (count: 1) | |
| The subfractionation of existing heparin preparations against anticoagulant activities (with proven low-toxicity profiles, good bioavailability and industrial-scale manufacturing) for off-label pathologies, provides an attractive strategy for quickly and effectively responding to COVID-19 and for the development of next generation heparin-based therapeutics.
| |
| we | provide | overview of landscape of therapeutic research for COVID-19 (count: 1) | |
| To provide an overview of the landscape of therapeutic research for COVID-19, we conducted a review of registered clinical trials.
-- reference not found! | |
| DIP | may provide | therapeutic benefits to COVID-19 patients (count: 1) | |
| 22 Apart from the well-known antiplatelet function, DIP may 101 provide additional therapeutic benefits to COVID-19 patients.
-- Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medrxiv. 2020-02-29. | |
| its 345 therapeutic use | is in | COVID-19 (count: 1) | |
| Moreover, 344 the wide availability, safety and affordability of DIP argue for further investigation into its 345 therapeutic use in COVID-19, particularly in the event of its rapid spread into the developing XH, YZ, FZ, and HBL co-designed the study and co-led overall data interpretation.
-- Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medrxiv. 2020-02-29. | |
| efforts | develop therapeutics | fight against COVID-19 (count: 1) | |
| While the world are jointing efforts to develop diagnostics, therapeutics, and vaccines to fight against COVID-19, information about cultivation, purification and super molecular structure of SARS-CoV-2 in their native state is in need urgently.
-- Viral Architecture of SARS-CoV-2 with Post-Fusion Spike Revealed by Cryo-EM. biorxiv. 2020-03-05. | |
| nucleotide analogues | be evaluated as | potential therapeutics for COVID-19 (count: 1) | |
| These results offer a strong molecular basis for these nucleotide analogues to be evaluated as potential therapeutics for COVID-19.
-- reference not found! | |
| therapeutic strategy | reduce | mortality characteristics SARS-CoV-2 (count: 1) | |
| Our clinical and pathological review of COVID-19 can help healthcare worker to formulate a timely therapeutic strategy for similar patients and reduce mortality Pathological characteristics SARS-CoV-2 has been identified as a sister virus to SARS-CoV, a SARS-related coronavirus (SARSr-CoV).
-- reference not found! | |
| SARS-CoV-2 | have | mechanism of action (count: 1) | |
| In addition, Ding et al[50, 51] also found SARS-CoV in systemic endocrine gland, Because SARS-CoV and SARS-CoV-2 have the same mechanism of action, they can cause rapid production of multiple cytokines in body fluids after infection with microorganisms, leading to acute respiratory distress and multiple organ failure.
-- reference not found! | |
| we | conducted literature review In | view of outbreak of coronavirus 2019-nCoV (count: 1) | |
| Out of these 62% of patients with ILI in whom viruses have been identified, In view of the current outbreak of novel coronavirus 2019-nCoV, and given the need for plausible parameters for modeling efforts, we conducted an in-depth literature review for human coronavirus.
| |
| therapeutic design efforts | using | 2019-nCoV S proteins (count: 1) | |
| Despite the relatively high degree of structural homology suggests that SARS-directed mAbs will not necessarily be cross-reactive and that future antibody 115 isolation and therapeutic design efforts will benefit from using 2019-nCoV S proteins as probes.
-- Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. biorxiv. 2020-02-15. | |
| risk factors | suggest | therapeutic intervention for patients with COVID-19 (count: 1) | |
| Given the regional disparity of COVID-19, we aim to describe epidemiological, clinical, laboratory, and radiological features, treatment, and prognosis of COVID-19 patients in Chongqing municipality, and compare the differences between non-severe and severe patients, which may unravel risk factors associated with 28-day mortality and further suggest a specific therapeutic intervention for patients with COVID-19 in Chongqing municipality, China.
| |
| therapeutic effects | is in | patients infected by 2019-nCoV (count: 1) | |
| It may also be worth investigating the therapeutic effects of dipyridamole in patients infected by 2019-nCoV.
| |
| Outcome reporting | is in | protocols of clinical trials of COVID-19 (count: 1) | |
| Outcome reporting in protocols of clinical trials of COVID-19 is inconsistent.
-- Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review. medrxiv. 2020-03-08. | |
| aim | provide | list of outcomes for clinical trials of COVID-19 (count: 1) | |
| The aim of this review was to provide a list of outcomes for clinical trials of COVID-19, both interventions of Traditional Chinese Medicine and western medicine were considered.
-- Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review. medrxiv. 2020-03-08. | |
| review | provide | review on 2019-nCoV infection therapeutic options (count: 1) | |
| This review provide an authoritative review on 2019-nCoV infection therapeutic options.
-- reference not found! | |
| 2019-nCoV/SARS-CoV | suggesting | potential drug targets for therapeutic development (count: 1) | |
| A recent study showed that 2019-nCoV/SARS-CoV-2 is able to utilize ACE2 as an entry receptor in ACE2-expressing cells 33 , suggesting potential drug targets for therapeutic development.
-- reference not found! | |
| therapeutic alternatives | are required Due to | spread of SARS-CoV-2 (count: 1) | |
| Due to the rapid spread of SARS-CoV-2, affecting more than 70 countries, therapeutic alternatives are urgently required.
-- reference not found! | |
| Combination therapy | can | can considered as therapeutic option for 2019-nCoV (count: 1) | |
| At present, efforts are being made to identify and develop monoclonal antibodies that are specific and effective against 2019-nCoV. Combination therapy with 2019-nCoV specific monoclonal antibodies and remdesivir can be considered as the ideal therapeutic option for 2019-nCoV (Cohen 2020) .
-- reference not found! | |
| therapeutics | efficacy against | 2019-nCoV (count: 1) | |
| A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.
-- Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. Journal of Clinical Medicine. 2020. | |
| Our work | validated | therapeutic target for COVID-19 pandemic (count: 1) | |
| Our previous work on SARS-CoV pathogenesis makes ACE2 a rational and scientifically validated therapeutic target for the current COVID-19 pandemic.
-- Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020. | |
| confusion | abounds in | therapeutic tactics employed in COVID-19 (count: 1) | |
| Much confusion abounds in the therapeutic tactics employed in COVID-19.
-- reference not found! | |
| therapeutic potential | is in | treatment of newly emerging COVID-19 (count: 1) | |
| Of note, in the mouse model of SARS-CoV infection, the remdesivir-resistant SARS-CoV lost less weight and had a more evident decline in pulmonary viral loads by four days after infection than wild-type SARS-CoV, indicative of attenuated pathogenicity of remdesivir-resistant SARS-CoV. The above findings indicate a high genetic barrier for remdesivir to develop resistance, decreased fitness and pathogenicity in the remdesivir-resistant mutants, and further encourage the therapeutic potential of remdesivir in the treatment of newly emerging COVID-19.
-- Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents. 2020-03-06. | |
| two randomized clinical trials | is in | treatment of COVID-19 (count: 1) | |
| reduction of pulmonary viral load in a murine model of SARS-CoV infection, potent antiviral activity against SARS-CoV-2, acceptable safety profile of parenteral remdesivir therapy in two case reports, and a randomized trial of Ebola virus disease, the clinical use of remdesivir in the cases of COVID-19 are highly anticipated; two randomized clinical trials of parenteral remdesivir therapy in the treatment of COVID-19 in China may open the window of effective antiviral therapy for such an epidemic infectious disease.
-- Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents. 2020-03-06. | |
| clinical trials | are testing chloroquine as | anti-COVID-19 therapy (count: 1) | |
| Currently, at least ten clinical trials are testing chloroquine as an anti-COVID-19 therapy [55] .
-- New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. International Journal of Antimicrobial Agents. 2020-03-12. | |
| therapeutic agents | treat | COVID-19 infection (count: 1) | |
| Thus, these therapeutic agents can be considered to treat COVID-19 infection [27] .
-- The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020-02-26. | |
| therapeutic strategy | should | For COVID-19 patients should formulated (count: 1) | |
| For the COVID-19 patients with diabetes, tailored therapeutic strategy and optimal goal of glucose control should be formulated based on clinical classification, coexisting comorbidities, age and other risk factors.
-- Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Research and Clinical Practice. 2020-03-13. | |
| suddenness | seriousness of | ~ 200 clinical trials on COVID-19 (count: 1) | |
| Considering the seriousness and suddenness of the COVID-19 outbreak, ~200 clinical trials on COVID-19 have commenced in China, and it is promising to report that certain targets and their agents have displayed strong antiviral potential, of which some have been permitted to be used in an attempt to combat the disease in clinical trials.
-- reference not found! | |
| clinical trials | evaluate | safety in treatment of COVID-19 (count: 1) | |
| 1 However, randomised clinical trials are needed to evaluate the safety and efficacy of remdesivir in the treatment of COVID-19.
-- Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases. 2020-02-27. | |
| Ran domised clinical trials | is in | treatment of COVID-19 (count: 1) | |
| Ran domised clinical trials for lopinavir/ ritonavir (ChiCTR2000029308) and intravenous remdesivir (NCT04257656, NCT04252664) in treatment of COVID-19 are currently in progress.
| |
| immunoglobulin | may | may considered as therapeutics for COVID-19 (count: 1) | |
| Intravenous immunoglobulin and Ta1 may also be considered as therapeutics for COVID-19.
-- reference not found! | |
| DFM | chairs NIHR for | COVID-19 for therapeutics (count: 1) | |
| DFM chairs the NIHR and Medical Research Council funding committee for COVID-19 for therapeutics and vaccines.
-- COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020-03-16. | |
| current anti-SARS-CoV-2 approach | is in | clinical trials (count: 1) | |
| Thus, successful demonstration of the efficacy of this current anti-SARS-CoV-2 approach in clinical trials would pave the way for use of the decoy cell platform to address a large number of unmet medical needs in the clinic as we seek to protect populations from viral, parasitic, fungal and bacterial diseases.
-- reference not found! | |
| answer | may offer | therapeutic management of COVID-19 virus (count: 1) | |
| The answer to this question may offer better, more effective therapeutic management, before lung involvement, of the COVID-19 virus.
-- reference not found! | |
| it | develop | COS for clinical trials on COVID-19 (count: 1) | |
| Hence, it is necessary to develop a COS for clinical trials on COVID-19 (COS-COVID), which is the aim of this study.
-- reference not found! | |
| evaluation | is in | clinical trials on COVID-19 (count: 1) | |
| Researchers are encouraged to apply the COS-COVID for the evaluation of different interventions (either pharmaceutical or non-pharmaceutical therapies) in clinical trials on COVID-19.
-- reference not found! | |
| Outcomes | adopted in | protocols clinical trials COVID-19 (count: 1) | |
| Outcomes adopted in the protocols of clinical trials on COVID-19.
-- reference not found! | |
| knowledge | consider | tsDMARDs as potential therapeutic strategies for COVID-19 (count: 1) | |
| The Authors also suggest that the increasing knowledge about the pathophysiology of Sars-coronavirus-2 (SARS-CoV-2) infection is leading to consider cs-, b-and tsDMARDs as potential therapeutic strategies for COVID-19 [1] .
-- reference not found! | |
| broad-spectrum antiviral drugs | have | have evaluated against COVID-19 in clinical trials (count: 1) | |
| However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery.
-- COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020-03-16. | |
| COVID-19 | develop | therapeutic strategy against SARS-CoV-2 (count: 1) | |
| Recently, mice models and clinical isolates were used to develop any therapeutic strategy against SARS-CoV-2 induced COVID-19 (46, 47) .
-- COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020-03-16. | |
| SARS-CoV-2 patients | conduct | clinical trials (count: 1) | |
| SARS-CoV-2 infected patients were also used to conduct randomized clinical trials (46, 49, 50) .
-- COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020-03-16. | |
| approved | therapeutics for | treatment of SARS-CoV-2 infection (count: 1) | |
| Currently, vaccines and approved targeted therapeutics for the treatment of the new SARS-CoV-2 infection are still lacking and the management of COVID-19 is only supportive, even though a multitude of compounds are now under investigation for the treatment of this emerging disease [75] .
-- reference not found! | |
| clinical trials | have | have registered in treatment of COVID-19 pneumonia (count: 1) | |
| Till now, several clinical trials have been registered on safety and efficacy of tocilizu mab in the treatment of severe COVID-19 pneumonia in adult inpatients , including a mult icenter, rando mized controlled trial for the efficacy and safety of tocilizu mab in the treat ment of novel coronary pneumonia (NCP) (Ch iCTR2000029765), a single arm open mu lticenter study on tocilizu mab (Ch iCTR2000030796), and comb ination of tocilizu mab and other drugs (Ch iCTR2000030442 and ChiCTR2000030894).
-- reference not found! | |
| therapeutics | may | may critical for response to 2019-nCoV outbreak (count: 1) | |
| In this review, we summarize the advance of the nature of the 2019-nCoV and its clinical characteristics and therapeutics, which may be critical for the response to the 2019-nCoV outbreak.
-- Coronavirus 2019-nCoV: A brief perspective from the front line. Journal of Infection. 2020-02-25. | |
| SARS-CoV-2-induced inflammatory response | is in | relation to timing of therapeutic interventions (count: 1) | |
| Finally, although 32.4% ( n = 90) of the reported 278 cases with SARS-CoV-2 pneumonia received systemic steroid therapy [4 , 5 , 8] , a study on the temporal features of the SARS-CoV-2-induced inflammatory response in relation to the timing of therapeutic interventions is lacking.
-- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents. 2020-03-31. | |
| clinical trials | have shown | 33 effective against COVID-19 (count: 1) | |
| Few clinical trials in 32 China have shown chloroquine phosphate, an aminoquinoline used in malaria treatment, to be 33 effective against COVID-19 at a dose of 500 mg/d [3].
-- reference not found! | |